Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Revolutionising Sustainable Energy Generation from Wastewater’s Sludge with a Novel, On-Site, Modular, Containerised Gasification Sludge-to-Energy System for Small to Medium-sized Treatment Plants (SHIT2POWER)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2100000.0
EU funding (EUR): 2100000.0
Participants: 1
Project status: SIGNED

We are set on revolutionizing the wastewater treatment sector with our groundbreaking on-site, modular, containerised gasification sludge-to-energy system, specifically designed for small to medium-sized treatment plants: the SHIT2POWER container. Europe faces a significant challenge in managing the 68 million tonnes of sludge produced annually. Traditional disposal methods are not only costly, reaching up to €230 per tonne, but also environmentally detrimental. Small to medium-sized wastewater treatment plants, serving populations of 5,000-30,000, are particularly burdened by high operational costs and energy consumption, comprising up to 35% of their annual expenses. Moreover, these plants are under increasing regulatory pressures to recover phosphorus and reduce their carbon footprints. Our innovative solution addresses these challenges with a patented reactor technology. The containerised system facilitates the thermochemical conversion of sewage sludge into synthesis gas, which is then used to generate heat and electricity. The process significantly reduces the volume of sludge, leaving behind biologically inactive and chemically stable ash suitable for safe disposal and phosphorus recovery. This not only mitigates the need for sludge transportation, thereby reducing associated CO2 emissions, but also generates renewable energy, alleviating the plants' reliance on traditional energy grids. Customers will benefit from substantial advantages such as reduced waste disposal costs and compliance with stringent EU regulations on phosphorus recovery and wastewater management. To further accelerate our market readiness and technological advancements, we are seeking EIC Accelerator support. The funding will catalyse our journey towards large-scale adoption, ensuring that small to medium-sized wastewater treatment plants can efficiently convert waste into a valuable resource, thereby promoting a sustainable, eco-friendly future for wastewater management in Europe.

Keywords: sewage sludge management,sludge to energy,thermochemical conversion,synthesis gas
Lubricant-infused surfaces in sUrfactant- and Bacteria-laden turbulent FLOWs (LUBFLOW)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Products and Processes Engineering
Panel description: Product and process design, chemical, civil, environmental, mechanical, vehicle engineering, energy processes and relevant computational methods
Countries involved: Sweden
Call: ERC CONSOLIDATOR GRANTS (ERC-2022-COG, 2022)
Start date: 2023-09-01
End date: 2028-08-31
Duration (months): 60.0
Total project cost (EUR): 1987355.0
EU funding (EUR): 1987355.0
Participants: 1
Project status: SIGNED

Robust surfaces that can resist fouling, reduce flow drag and control heat- and mass transfer in fluctuating flows would have broad technological implications, ranging from biomedical devices and marine industry to food processing and batteries. Slippery surfaces that use microstructures to lock in place a lubricating liquid hold great promise as a breakthrough technology. In gentle conditions, they have already demonstrated anti-fouling, drag reduction and heat-transfer enhancement. However, when submerged in harsh flow environments that contain turbulence, surfactants and microorganisms, these surfaces drastically change their behavior. The lubricant-liquid interface can break up and partially drain resulting in self-emergent surface patterns. It can sustain large capillary waves resulting in surface roughness. It can change or obtain new properties from Marangoni stresses and it can allow the partial attachment of biofilms. Understanding these non-equilibrium states of lubricant-infused surfaces will lead to mitigation of failure modes and to new functionalities of lubricant-infused surfaces, including controlling non-colloidal particles or serving as surface actuators. Therefore, the aim of this project is to provide a deep understanding of lubricant-liquid phenomena in harsh flow environments and lead the way to a new generation of functional surfaces for fluid flows. We will use a unique combination of high-performance computing and flow experiments to untangle the interaction between the tiny scales of liquid-liquid interfaces, large flow patterns, the existence of “hidden” surfactants and the active decisions made by settling bacteria. By establishing the fundamental behavior of lubricant-infused surfaces in dynamic and realistic environments, we pave the way to control transport processes in submerged applications.

Keywords: slippery surfaces,turbulence,interfacial instabilities,biofilms,marangoni stress
In-depth automated characterization for process development and quality control of cell therapies. (CYTESTAMP)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Italy
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Cell therapy is a revolution in the pharmaceutical industry. Cell therapy is a type of immunotherapy treatment where patient’s immune cells are genetically engineered or modified to recognize proteins found on specific tumor cells and so induce a targeted and persistent killing effect once re-infused in the patient. Cellply’s ambition is to be a leading provider of analytical characterization tools supporting the development and manufacturing of cell therapies. The strategy is to provide a portfolio of products for end-to-end characterization of cell therapies, from discovery to commercialization. The products integrate patented microfluidics, robotic and AI technologies to deliver a unique depth of analysis and data to inform drug developers throughout therapy development. Cellply launched its flagship VivaCyte® R&D to address the specific needs of early research and development where new cell therapies are discovered and optimized for certain characteristics such as potency and longevity. Next is to scale the platform out to the PD (Process Development) and to the QC (Quality Control) areas, while expanding commercial activities in EU and US to increase the platform’s user base. USP1: VivaCyte allows comparison of process options for these live cell therapies at high throughput, with minimal hands-on time, in compliance with industry regulations. USP2: VivaCyte is the first lab-in-a-box system automating potency and cell-based release assays in a walk-away format to remove a critical manufacturing bottleneck. Cellply product strategy allows it to address multiple market segments in the next 3 years: discovery & PD (represented by 1.200 biopharma & institutes); translational R&D (represented by 1.800 clinical trials and 80.000 patients); Quality control in cell therapy manufacturing (with 6 approved products, 1.800 clinical trials and 95.000 patients) - the industry’s highest growth segment by size of drug product pipeline.

Keywords: diagnostic tools
TRIOP: an intraoperative probe to assess tumor margins and remove tumor residues in real time (TRIOP)

Framework: Horizon Europe — Innovative Europe
Programme: European innovation ecosystems
Theme: Elevating the scalability potential of European business
Destination: Elevating the scalability potential of European business
Action type: Coordination and support actions
Countries involved: France
Call: Women TechEU (HORIZON-EIE-2022-SCALEUP-02, 2022)
Start date: 2023-07-01
End date: 2024-03-31
Duration (months): 9.0
Total project cost (EUR): 107142.86
EU funding (EUR): 75000.0
Participants: 1
Project status: CLOSED

Cancer is the 2nd most common cause of death worldwide. Oncological surgery is the most efficient single-treatment and is the most used as primary treatment. However, the local cancer recurrence rate after the first surgery is still high in every organ. Local cancer recurrence is mainly caused by tumor growth from remaining tumor residues. They have a major impact on survival, quality of life and require reinterventions and/or adjuvant treatments. Therefore, the main issue today in oncological surgery today is to ensure the resection quality and remove the whole tumor while minimizing healthy tissues removal. To achieve it, surgeons need real time information on tumor residues’ location. Beams is a medtech company, incorporated on the 17th of May 2021 to answer this unmet medical need. Beams develops TRIOP (Tumor Resection IntraOperative Probe) technology, a miniaturized intraoperative probe which measures the accumulation of existing radiotracers in tumor tissues after their injection in the organism, and then informs surgeons in real time about the precise tumor localization to help removing the tumor while preserving surrounding healthy tissues. The targeted impact is to prevent local cancer recurrence and to preserve patients’ quality of life. The first Beams’ product based on TRIOP technology will be a multi-purpose intelligent surgical aspirator: the detection system will be built around an aspiration tool, to remove tumor cells, blood and other secretions that could alter the detection simultaneously with examining the operative cavity.
Relu’s Automatic Surgical Implant Guide Algorithm (RASIGA)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Belgium
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Every year, the global population loses 1.34 billion teeth, which is increasing according to the WHO. For both physical and mental health of patients, these teeth need to be replaced. However, dentists often lack the confidence to place dental implants due to associated risks like infection and paralysis, which leads to patients being referred to specialists, leading to long waiting lists and increased costs. Luckily, a tool called a surgical implant guide exists that offers a solution to place implants safely, empowering general dentists to place implants as well. These surgical guides remain costly and time-consuming to make, thereby limiting their accessibility. Therefore, Relu developed an AI-based software called RASIGA that automates the entire design of surgical implant guides. It can be installed as a plug-in, thereby seamlessly integrating with existing dental software. By uploading standard imaging scans such as CBCT and intra-oral scans, a digital twin is automatically generated and several propositions for the position of the new crowns, ideal placement of the implant(s) and design of the surgical guide are generated. This significantly reduces the complexity and time to make surgical guides, which empowers many more dentists to place implants safely and qualitatively. Currently, few competitors provide such automatic implant surgery planning, and no competitor delivers similar technology as a plug-in, giving Relu a unique position in the market. Relu's need for EIC support is driven by venture capital funds' limited expertise in the dental industry and Relu's currently limited revenue as a scale-up to deploy a medical device in this highly regulated market. We will be the first to enter the market with a B2B2B solution, which turns the current market leaders into clients instead of competitors. Our solution has the potential to bring dental implant expertise to every dentist in the world. For these reasons, Relu is applying for EIC Accelerator funding.

Keywords: artificial intelligence,dentistry,surgical guides,dental implants,deep tech,automation,algorithms,cloud service,genetic algorithms,neural networks,medical compliance,crown design
Transforming Agri-Food By-Products into High-Nutritional Value, Sustainable Proteins and Ingredients (MOA FOODTECH)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Challenges
Action type: EIC actions
Countries involved: Spain
Call: Food from precision fermentation and algae (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2025-06-01
End date: 2027-05-31
Duration (months): 24.0
Total project cost (EUR): 3225737.14
EU funding (EUR): 2258016.0
Participants: 1
Project status: SIGNED

MOA Foodtech: Pioneering Sustainable Food Solutions Founded in 2020, MOA Foodtech is revolutionizing the food industry by creating sustainable proteins and ingredients to address global challenges. Backed by €4.26 million in venture capital and €1.928 million in grants, we are supported by leading investors like Barilla and ICOS Capital. With 27 pilot projects and 5 license agreements with major players like Nestlé and Barilla, MOA is shaping the future of food production. The Global Food Challenge By 2050, the world’s population will hit 9.2 billion, driving a 70% increase in protein demand. Traditional agriculture, which already occupies 77% of global farmland and contributes up to 30% of greenhouse gas emissions, cannot sustainably meet this need. MOA’s solution offers an alternative through innovative fermentation techniques, drastically reducing environmental impact. MOA’s Breakthrough Technology Our Non-GMO Directed Fermentation platform combines the benefits of both biomass and precision fermentation, without regulatory delays. Powered by our AI platform, Albatros, it allows us to produce high-quality, customizable ingredients using pre-approved microorganisms, ensuring faster, cost-effective production. This innovation positions us as a leader in sustainable food ingredients, with products that are scalable and market-ready. High-Growth Potential MOA operates in the fast-growing €511 billion food ingredients market, targeting a Serviceable Obtainable Market of €516 million in Europe and North America. We seek €2.258 million in grant funding and €12.5 million in equity from the EIC Accelerator to scale production and drive commercialization. With our cutting-edge technology and a clear growth strategy, MOA is set to lead the future of sustainable food innovation.

Keywords: alternative proteins,ingredients,fermentation,food tech
Innovative modular hardware development platform (Rhomb)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Spain
Call: Open Disruptive Innovation Scheme (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2017-02-01
End date: 2017-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

European ICT companies developing hardware products are currently dealing with important challenges which affect to their competitiveness: high innovation costs and lack of financing, tight margins and brief life-cycles of their products, among others. Companies, especially SMEs, find strong difficulties to get funding for their ICT hardware projects and current time-to-markets make impossible to be competitive against Asian and US companies. Corporations that need customised hardware solutions for specific applications must usually adopt standard solutions which do not completely satisfy their specifications due to the high costs and technical difficulties of developing tailored products. As a solution for said problems TNFG, a Spanish SME specialised in the development of high quality hardware solutions for the creation of electronic devices, has developed Rhomb. Rhomb is a modular, multi architecture, miniaturised hardware development system with which makers, start-ups and technology based companies can create their own electronic devices with reduced investment requirements (50% less) and short time-to-market (1/3 of time) compared to current solutions. Rhomb is aimed to become a new technological reference for the development of all kinds of electronic devices, entering a worldwide market of more than $ 1,000 billion.

Keywords: electronics,modular,device,development platform,core,module,computer
Mutation rate evolution in attine ants (MutANTs)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2020-09-01
End date: 2022-08-31
Duration (months): 24.0
Total project cost (EUR): 219312.0
EU funding (EUR): 219312.0
Participants: 1
Project status: CLOSED

Germline mutation rate (GMR) is a key concept in all disciplines of biology, and particularly in evolutionary biology and the biomedical sciences. GMR varies both across and within species, but what drives this variation is unclear. Theories predict that GMR variation is shaped by environmental selection pressures, by effective population sizes, and by prevailing life-history traits (across species) and parental age at reproduction (within species). However, our understanding is extremely limited because within-species GMR variation has been investigated only to some extent in humans, and larger comparative genome-level datasets in other clades have not yet been pursued. I propose to start filling this gap by studying GMR in attine fungus-growing ants and a set of outgroup. non-attine ants. The attine ants, a ca. 55 MY old monophyletic lineage, are ideal for understanding GMR variation across and within species because their basic ecology is similar (obligate dependence of farmed fungi for food) but their life-histories diversified enormously from the base to the crown of their phylogenetic tree, which presently has 15 recognized genus-level branches and >230 species. Against a background dataset of ~20 high quality genomes, I propose to obtain genome-wide GMR estimates for 12 attine ants and 7 non-attine ants while controlling for confounders of phylogeny, colony size, life-span and effective population size. In addition, I will do an in-depth analysis of a single leafcutter ant species with long-lived queens and stored sperm of the same age, where I can also control for parental age. I will implement the MutANTs project at the Centre for Social Evolution in Copenhagen, an internationally renowned research hub for interdisciplinary omics research on ants, with Professors Guojie Zhang and Jacobus Jan Boomsma as joint hosts. I expect that in the two years available MutANTs will yield the first comparative data to predict GMRs across and within species.

Keywords: mutation rate,ants,macro evolution,pedigree based resequencing,life history,ecology
Safe and Sensible Tissue Graspers for Pediatric and (Mini-)Laparoscopic Surgery (SensAtouch Grasper)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Netherlands
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2019-02-01
End date: 2019-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Laparoscopic surgery is the most common surgical intervention with over 15 million procedures performed annually worldwide. Most recently, the Dutch Healthcare Inspectorate shocked the medical community when discovering the risk of patient complications is 2-4% higher per laparoscopic operation as compared to its outdated equivalent, open abdominal surgery. Patient post-operative complications are the most costly of medical errors, increasing hospital costs by € 15 Billion per year in EU/US, with €6 Billion directly contributed by 5 laparoscopic procedures. Clinical research acknowledges that state-of-the-art graspers lack force feedback capabilities, which is responsible for accidental tissue trauma, a primary factor of post-operative complications. In fact, it is observed that 38% of all grasper movements are unsuccessful, meaning the surgeon is unable to perform the desired action without repeated clamping, slip, or obvious tissue trauma. MMI is commercializing a new line of force feedback surgical graspers that replaces the root technology of state-of-the-art to address the immediate clinical needs, while converging onto three business trends in the market. The SensAtouch grasper is more sensitive, cost effective, and can be diametrically miniaturised without loss of performance. The SensAtouch technology operates on the same working principles as state-of-the-art instruments and is attachable onto the vast majority of commercially-available grasper handles. Therefore, this innovation will disrupt the laparoscopic device market by enhancing safety and effectiveness, while maintaining operating room dynamics and medical device supply chains. The SensAtouch grasper can be procured without added costs to the hospital, while reducing post-operative complication costs up to € 6 Billion in the EU/US annually. The entry market of pediatric surgery opens direct access into the mini- and general laparoscopic device markets valued globally at € 8.9 billion in 2017.